Xeroderma Pigmentosum Complementation Group F Polymorphisms Influence Risk of Glioma


We conducted an exploratory investigation of whether variation in six common SNPs of xerodermapigmentosum complementation group F (XPF) is associated with risk of glioma in a Chinese population. Sixsingle nucleotide polymorphisms (SNPs) were genotyped in 207 glioma cases and 236 cancer-free controls by a384-well plate format on the Sequenom MassARRAY platform (Sequenom, San Diego, USA). The rs1800067G and rs2276466 G allele frequencies were significantly higher in the glioma group than controls. Individualswith the rs1800067 GG genotype were at greater risk of glioma when compared with the A/A genotype in thecodominant model, with an OR (95% CI) of 2.63 (1.04-7.25). The rs2276466 polymorphism was significantlyassociated with moderate increased risk of glioma in codominant and dominant models, with ORs (95% CI) of1.90 (1.05-3.44) and 1.55 (1.07-2.47), respectively. The combination genotype of rs1800067 G and rs2276466 Galleles was associated with a reduced risk of glioma (OR=0.44, 95% CI=0.19-0.98). These findings indicate thatgenetic variants of the XPF gene have critical functions in the development of glioma.